Value of Life Science Patents Debated.
DuBois, who also holds an undergraduate degree in chemical engineering and is admitted to practice before the United States Patent and Trademark Office, will join valuation expert Mike Pellegrino of Pellegrino & Associates, author of an upcoming guide on the subject, during a 100-minute interactive teleconference on December 11.
Speaking to attorneys and business valuation professionals, DuBois and Pellegrino will discuss and take questions on the critical and intertwined issues around valuing intellectual property, the variables that influence value and exposure, as well as managing the risk of an IP portfolio.
"Science for science's sake brings no value," said Pellegrino, who has extensive experience valuing IP assets for life science and Fortune 500 companies. "New invention must have a value proposition that focuses on a novel therapy, better efficacy, lower manufacturing cost, or a lower overall treatment cost to have any market traction."
The following subjects will be addressed: wading through the science to get to the value proposition; understanding the impacts of the regulatory process on value; risk assessment for value development; unique challenges in the pharmaceutical and medical device space; market adoption modeling; building an IP portfolio of value; understanding infringement risks; and due diligence considerations.
BVR Legal is a division of Business Valuation Resources LLC, and provides legal and financial education programs in the areas of complex business litigation, insurance, reinsurance and tort law.
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Date:||Oct 1, 2008|
|Previous Article:||MiddleBrook Announces Orange Book Listing of Moxatag Patents.|
|Next Article:||Cavitation Biodiesel Technology Available for Sale.|
|Biopiracy: the plundering of nature and knowledge.|
|Patents, paradigm shifts, and progress in biomedical science.|
|To patent or not to patent.|